bricanyl turbohaler 500mcgs per metered dose inhalation powder
associated drug co. limited triq l-esportaturi, zone 1 central business district birkirkara cbd 1040 , malta - terbutaline sulfate - inhalation powder - terbutaline sulfate 500 µg/spray - drugs for obstructive airway diseases
magnesium sulfate in dextrose- magnesium sulfate injection
wg critical care, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the effect of intravenous magnesium on milk production is unknown. the developmental and health benefits to the neonate of breastfeeding should be considered along with the mother's clinical need for magnesium sulfate in 5% dextrose injection and any potential adverse effects on the breastfed infant from magnesium sulfate in 5% dextrose injection or from the underlying maternal condition. the safety and effectiveness of magnesium sulfate in 5% dextrose injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. dosing recommendation in pregnant adolescent patients are the same as for pregnant adult patients [see dosage and administration (2.2)] . magnesium is excreted solely by the kidneys. patients with severe renal impairment (urine output less than 100 ml per 4 hours) are at greater risk for increased magnesium concentrations that may lead to magnesium toxicity [see warnings and precautions (5.2) and clinical pharmacology (12.3)] . in patients with severe renal impairment, dosage reduction is recommended and the maximum recommended dosage is lower than patients with normal renal function [see dosage and administration (2.3)] .
magnesium sulfate in dextrose injection, solution
hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 10 mg in 1 ml - magnesium sulfate in 5% dextrose injection is indicated for: magnesium sulfate in 5% dextrose injection is contraindicated in patients: risk summary magnesium sulfate in 5% dextrose injection is indicated in pregnant women for the prevention of eclampsia in women with preeclampsia and the treatment of seizures and prevention of recurrent seizures in women with eclampsia. fetal, neonatal, and maternal risks are discussed throughout the labeling. clinical considerations labor or delivery: magnesium sulfate in 5% dextrose injection is not approved for the treatment of pre-term labor. administration of magnesium sulfate in 5% dextrose injection to pregnant women longer than 5 to 7 days may lead to hypocalcemia and bone abnormalities in the developing fetus, including skeletal demineralization and osteopenia [see warnings and precautions (5.1)] . the use of intravenous magnesium in pregnant women increases human milk magnesium concentrations only slightly and oral absorption of magnesium by the infant is poor. the
bricanyl turbohaler 500 microgram powder for inhalation
b & s healthcare - terbutaline sulfate - powder for inhalation - 500 microgram
bricanyl turbohaler 500 micrograms per metered dose, inhalation powder
imbat limited - terbutaline sulfate - powder for inhalation - 500 mcg/acutuation - selective beta-2-adrenoreceptor agonists; terbutaline
bricanyl
astrazeneca limited - terbutaline sulfate 0.3 mg/ml - elixir - 1.5 mg/5ml - active: terbutaline sulfate 0.3 mg/ml excipient: citric acid citric acid monohydrate disodium edetate dihydrate ethanol lemon-limette glycerol purified water raspberry sodium benzoate sodium hydroxide sorbitol
bricanyl
astrazeneca limited - terbutaline sulfate 0.5 mg/ml - solution for injection - 0.5 mg/ml - active: terbutaline sulfate 0.5 mg/ml excipient: sodium chloride water for injection
bricanyl
astrazeneca limited - terbutaline sulfate 2.5mg - tablet - 2.5 mg - active: terbutaline sulfate 2.5mg excipient: ethanol lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water
bricanyl
astrazeneca limited - terbutaline sulfate 5mg - tablet - 5 mg - active: terbutaline sulfate 5mg excipient: ethanol lactose monohydrate magnesium stearate maize starch microcrystalline cellulose povidone purified water
bricanyl aerosol
astrazeneca limited - terbutaline sulfate 0.25mg - aerosol inhaler, metered dose - 0.25 mg/dose - active: terbutaline sulfate 0.25mg excipient: cryofluorane dichlorodifluoromethane sorbitan trioleate trichlorofluoromethane